Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
28 Aug 2025
Cell and gene therapies on correction course but not sinking
When the first gene therapy using CRISPR was approved in the US in 2023, former President Joe Biden struck an optimistic tone. “This holds tremendous promise for developing additional life-saving…
22 Aug 2025
Animal testing alternatives to dominate, but not overnight
In a bid to prioritise more human-relevant models, the US Food and Drug Administration (FDA) has enforced a plan to phase out animal testing for monoclonal antibodies (mAbs) in the…
22 Aug 2025
Magazine: Big biopharma take on the ADC challenge
Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040. However, technical hurdles in the field…
18 Aug 2025
Accelerating diagnosis and drug development with better managed datasets
Every aspect of science and research is based on data, and across the globe, labs are producing more data than the average person can even comprehend. With the increasing digitalisation…
13 Aug 2025
A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still the deadliest gynaecologic cancer, claiming about 13,000 U.S. lives each…
12 Aug 2025
Podcast: US tariff news and Q2 earnings influence pharma trends
After months of negotiations, the EU and US reached an agreement to levy a 15% tariff on EU imports, which includes including tariffs on specific sectors, like the drug imports. …